Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial.

ABSTRACT:

Background

In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional efficacy endpoints in pre-treated participants with pulmonary arterial hypertension (PAH).

Methods

This post hoc analysis evaluated data from right heart catheterisation (RHC) and echocardiography (ECHO) obtained from the STELLAR trial. Changes from baseline in RHC and ECHO parameters were assessed at 24 weeks. An analysis of covariance (ANCOVA) model was used to estimate differences in least squares means with treatment and randomisation stratification (mono/double versus triple therapy; World Health Organization functional class II versus III) as fixed factors, and ba

SUBMITTER: Souza R 

PROVIDER: S-EPMC10512088 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature